Shenzhen, China, June 17, 2025 (GLOBE NEWSWIRE) -- Meiwu Technology Company Limited (“WNW” or the “Company”), (NASDAQ: WNW) announced today that today that it entered into an agreement with Shenzhen Zhinuo Weichuang Technology Co., Ltd.(“Zhinuo Weichuang”) to enhance the Company’s brand influence and market competitiveness. Zhinuo Weichuang, based in Guangdong China, primarily engages in the research, development, and sale of technology products in the fields of smart technology, AI-driven finance, and the ...

根据披露的部分数据，Founders Fund 连续 4 只基金的 DPI 都超过了 5 倍。而 The Generalist 创始人 Mario Gabriele 经过一年多的研究后，最近写了一篇关于 Founders Fund 的长文（完整版还没发 布）。 Founders Fund 在 2007、2010 和 2011 年的基金分别获得了 26.5 倍、15.2 倍和 15 倍的回报 。 我之前在这篇文章《 OpenAI 花 30 亿美金收购深入 AI 编程，a16z 和 FF 募巨资 VC 行业走出衰退 》 里介绍过 Founders Fund 以及其他一些 VC 的业绩数据。 其中 Founders Fund 因为一直以来持续的好业绩受到了 LP 的追捧，以至于最新一期 Growth 基金出现 了 16 亿美金的超额认购，本来打算募集 30 亿美金的规模最后募集了 46 亿美金。 而获得如此好的业绩，我觉得下面这张图差不多解释了大部分原因，因为 Peter Thiel 真金白银 Skin in The Game。2005 年的第一期基金，Peter Thiel 个人出资额占到了整个基金的 76%，基 ...

Let me start by asking you all something. Have you at least once in your life, I know you're all very young, but at any point in your life, have you asked yourself this question? And the question is, who am I? Who am I? Sounds like a simple question, right? You see, the moment you're born, you're welcomed into a world that pretty much tells you who you are. You are enrolled into school by the time you're just 3 or 4 years old. And there are these milestones that are set on your path. And you're expected to ...

Medicus Pharma Ltd. to Present at 2025 Bio International ConventionCompany Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025June 12, 2025 7:30 AM EDT | Source: Medicus Pharma Ltd.Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention.Event DetailsDate: Tuesday, ...

CytomX Therapeutics (CTMX) 2025 Conference June 05, 2025 02:35 PM ET Speaker0 All right. All right. Welcome, everyone, to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Sung, one of the senior analysts cover SMICHA Biotech in The US. It is my pleasure to have the next fireside chat with Atomic Therapeutics CEO, Sean. Good. Yeah. Good to see you. Speaker1 Pleasure to be here, Roger. Speaker0 Awesome. Maybe before we start, we know you just announced a very exciting data from your ...

KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24 Even patients with milder ...

The cosmetics seller reported a nearly 50% increase in its first-quarter revenue from skincare products as it pivots to the segment from make-upKey Takeaways:Yatsen's first-quarter net loss narrowed sharply to less than $1 million, as it reported a profit on a non-GAAP basisSkincare products accounted for 43.5% of the cosmetics seller's net revenue for the quarter, up from 31.7% a year earlierWhen Yatsen Holding Ltd. (YSG.US) Chairman Huang Jinfeng declared his company was on the cusp of a turnaround in Apr ...

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAEMay 22, 2025 7:30 AM EDT | Source: Medicus Pharma Ltd.Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NAS ...

MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY: Date: Wednesday, June 4, 2025 Time: 12:50PM ET A webcast and replay of Oruka's presentation will be available on the Oruka investor events websit ...

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases ...